Last reviewed · How we verify
Ilomedin and standard low dose treatment — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Ilomedin and standard low dose treatment (Ilomedin and standard low dose treatment) — Thrombologic ApS.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ilomedin and standard low dose treatment TARGET | Ilomedin and standard low dose treatment | Thrombologic ApS | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ilomedin and standard low dose treatment CI watch — RSS
- Ilomedin and standard low dose treatment CI watch — Atom
- Ilomedin and standard low dose treatment CI watch — JSON
- Ilomedin and standard low dose treatment alone — RSS
Cite this brief
Drug Landscape (2026). Ilomedin and standard low dose treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/ilomedin-and-standard-low-dose-treatment. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab